China NMPA Product Recall - Defibrillation Lead

On November 18, 2021, the National Medical Products Administration (NMPA) in China announced a Class III voluntary recall initiated by Medtronic Inc. The recall, reported by Medtronic (Shanghai) Management Co., Ltd., specifically targets certain models and batches of Medtronic's implantable defibrillation leads. The primary reason for this action stems from identified labeling and compliance issues associated with these devices. While the document does not specify inspection dates, the recall publication date serves as the announcement timeline. A Class III recall, under the NMPA's regulatory framework, indicates that the use of or exposure to the affected product is unlikely to cause adverse health consequences. Medtronic Inc. is required to provide detailed information regarding the specific models, specifications, and batch numbers of the affected products in an attached "Medical Device Recall Event Report Form," ensuring transparency and facilitating the necessary corrective actions for these critical medical devices.